Pär Stattin

27.8k total citations · 2 hit papers
419 papers, 16.8k citations indexed

About

Pär Stattin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Pär Stattin has authored 419 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Pulmonary and Respiratory Medicine, 143 papers in Oncology and 89 papers in Molecular Biology. Recurrent topics in Pär Stattin's work include Prostate Cancer Treatment and Research (210 papers), Prostate Cancer Diagnosis and Treatment (172 papers) and Cancer, Lipids, and Metabolism (57 papers). Pär Stattin is often cited by papers focused on Prostate Cancer Treatment and Research (210 papers), Prostate Cancer Diagnosis and Treatment (172 papers) and Cancer, Lipids, and Metabolism (57 papers). Pär Stattin collaborates with scholars based in Sweden, United States and United Kingdom. Pär Stattin's co-authors include Anders Bergh, Pernilla Wikström, Hans Garmo, Göran Hallmans, Lars Egevad, Rudolf Kaaks, Jan Adolfsson, David Robinson, Ola Bratt and Jan‐Erik Damber and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Pär Stattin

410 papers receiving 16.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

2011 381 citations Pär Stattin, Anders Widmark et al. PLoS ONE profile →
Epidemiology and Prevention of Prostate Cancer

2021 325 citations Pär Stattin et al. European Urology Oncology profile →

Peers

Countries citing papers authored by Pär Stattin

Since Specialization

Citations

This map shows the geographic impact of Pär Stattin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pär Stattin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pär Stattin more than expected).

Fields of papers citing papers by Pär Stattin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pär Stattin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pär Stattin. The network helps show where Pär Stattin may publish in the future.

Co-authorship network of co-authors of Pär Stattin

This figure shows the co-authorship network connecting the top 25 collaborators of Pär Stattin. A scholar is included among the top collaborators of Pär Stattin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pär Stattin. Pär Stattin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient- and Procedure-specific Risk Factors for Urinary Incontinence After Robot-assisted Radical Prostatectomy: A Nationwide, Population-based Study 2025 ·European Urology Oncology ·(unknown), Rebecka Arnsrud Godtman, Stefan Carlsson, Pär Stattin, Johan Styrke, Marianne Månsson, Johan Stranne	1
2	Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden 2024 ·International Journal of Cancer ·Ulf Strömberg, Anders Berglund, Stefan Carlsson, Camilla Thellenberg Karlsson, Mats Lambe, Ingela Franck Lissbrant, Pär Stattin, Ola Bratt	4
3	Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study 2024 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Lars Egevad, (unknown), Brett Delahunt, Hemamali Samaratunga, (unknown), Hans Garmo, Pär Stattin, Martin Eklund	2
4	Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer 2024 ·British Journal of Urology ·Pär Stattin, (unknown), Xiwu Lin, Florence Lefresne, Sabine Brookman‐May, Suneel Mundle, (unknown), Dina Gifkins, David Robinson, Johan Styrke, Hans Garmo	0
5	Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy 2023 ·JAMA Network Open ·Christian Corsini, Hans Garmo, (unknown), Rolf Gedeborg, Pär Stattin, Marcus Westerberg	17
6	Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts 2023 ·British Journal of Cancer ·Josef Fritz, Sylvia H. J. Jochems, Tone Bjørge, Angela Wood, Christel Häggström, Hanno Ulmer, Gabriele Nagel, Emanuel Zitt, Anders Engeland, Sophia Harlid, Isabel Drake, Pär Stattin, Tanja Stocks	10
7	Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study 2023 ·JNCI Cancer Spectrum ·Casey Crump, Pär Stattin, James D. Brooks, Jan Sundquist, Alexis C. Edwards, Weiva Sieh, Kristina Sundquist	3
8	Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016 2020 ·Acta Oncologica ·Kerri Beckmann, Hans Garmo, Per Nilsson, Ingela Franck Lissbrant, Anders Widmark, Pär Stattin	10
9	Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden 2018 ·Scandinavian Journal of Urology ·Ingela Franck Lissbrant, Eugenio Ventimiglia, David Robinson, Magnus Törnblom, Marie Hjälm-Eriksson, Mats Lambe, Yasin Folkvaljon, Pär Stattin	12
10	Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer 2017 ·Journal of Clinical Oncology ·Stacy Loeb, Yasin Folkvaljon, Jan‐Erik Damber, Joseph P. Alukal, Mats Lambe, Pär Stattin	55
11	Primary cancers before and after prostate cancer diagnosis 2012 ·Cancer ·Mieke Van Hemelrijck, Linda Drevin, Lars Holmberg, Hans Garmo, Jan Adolfsson, Pär Stattin	23
12	Genetic Variants in the LEPR , CRY1 , RNASEL , IL4 , and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality 2011 ·Cancer Epidemiology Biomarkers & Prevention ·Daniel W. Lin, Liesel M. FitzGerald, Rong Fu, Erika M. Kwon, Siqun L. Zheng, Suzanne Kolb, Fredrik Wiklund, Pär Stattin, William B. Isaacs, Jianfeng Xu, Elaine A. Ostrander, Ziding Feng, Henrik Grönberg, Janet L. Stanford	55
13	Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients 2010 ·Clinical Cancer Research ·Peter Hammarsten, (unknown), Andreas Josefsson, Stina Häggström Rudolfsson, Pernilla Wikström, Lars Egevad, Torvald Granfors, Pär Stattin, Anders Bergh	49
14	Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer 2010 ·Cancer Prevention Research ·Robert J. Klein, Christer Halldén, Angel M. Cronin, Alexander Ploner, Fredrik Wiklund, Anders Bjartell, Pär Stattin, Jianfeng Xu, Peter T. Scardino, Kenneth Offit, Andrew J. Vickers, Henrik Grönberg, Hans Lilja	45
15	Fatty Acid Amide Hydrolase in Prostate Cancer: Association with Disease Severity and Outcome, CB1 Receptor Expression and Regulation by IL-4 2010 ·PLoS ONE ·Lina Thors, Anders Bergh, Emma Persson, Peter Hammarsten, Pär Stattin, Lars Egevad, Torvald Granfors, Christopher J. Fowler	62
16	A Novel Prostate Cancer Susceptibility Locus at 19q13 2009 ·Cancer Research ·Fang‐Chi Hsu, Jielin Sun, Fredrik Wiklund, Sarah D. Isaacs, Kathleen E. Wiley, Lina D. Purcell, Zhengrong Gao, Pär Stattin, Yi Zhu, Seong‐Tae Kim, Zheng Zhang, Wennuan Liu, Bao-Li Chang, Patrick C. Walsh, David Duggan, John D. Carpten, William B. Isaacs, Henrik Grönberg, Jianfeng Xu, S. Lilly Zheng	36
17	Association of a Germ-Line Copy Number Variation at 2p24.3 and Risk for Aggressive Prostate Cancer 2009 ·Cancer Research ·Wennuan Liu, Jishan Sun, Ge Li, Yi Zhu, (unknown), Seong‐Tae Kim, Jielin Sun, Fredrik Wiklund, Kathleen E. Wiley, Sarah D. Isaacs, Pär Stattin, Jianfeng Xu, David Duggan, John D. Carpten, William B. Isaacs, Henrik Grönberg, S. Lilly Zheng, Bao-Li Chang	58
18	Insulin-like Growth Factor-II Methylation Status in Lymphocyte DNA and Colon Cancer Risk in the Northern Sweden Health and Disease Cohort 2009 ·Cancer Research ·Rudolf Kaaks, Pär Stattin, Stéphanie Villar, Anna R. Poetsch, Laure Dossus, Alexandra Nieters, Elio Ríboli, Richard Palmqvist, Göran Hallmans, Christoph Plass, Marlin D. Friesen	25
19	Sequence Variants at 22q13 Are Associated with Prostate Cancer Risk 2008 ·Cancer Research ·Jielin Sun, Siqun L. Zheng, Fredrik Wiklund, Sarah D. Isaacs, Ge Li, Kathleen E. Wiley, Seong‐Tae Kim, Yi Zhu, Zheng Zhang, Fang‐Chi Hsu, Aubrey R. Turner, Pär Stattin, Wennuan Liu, Jin Woo Kim, David Duggan, John D. Carpten, William B. Isaacs, Henrik Grönberg, Jianfeng Xu, Bao‐Li Chang	79
20	Ratios of IGF-I, IGF Binding Protein-3, and Prostate-Specific Antigen in Prostate Cancer Detection 2001 ·The Journal of Clinical Endocrinology & Metabolism ·Pär Stattin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact